Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic Reports Preliminary Gene Expression Blood Test Study Data

NEW YORK (GenomeWeb News) – Norwegian biotech company DiaGenic presented preliminary data from its Indian breast cancer gene expression blood test study at a meeting in New Delhi today.
So far the results — based on 113 subjects — suggest DiaGenic’s test is as effective for diagnosing breast cancer in Indian populations as it is in other populations tested, the company said. The firm plans to enroll a total of 720 subjects in the ongoing, multi-center study. The company reported its findings at the Federation of Obstetrics and Gynecology Societies of India’s annual meeting.
The DiaGenic test detects breast cancer by measuring secondary gene expression changes from venous blood samples. This gene expression signature was initially identified in Scandinavian and American patients. Developers are touting the test as an accurate alternative to mammography in pre-menopausal women, who tend to have dense breast tissue that obscures mammography images.
The company plans to complete the study within the next few months and said it may eventually market the test in India, where breast cancer often occurs at younger ages than it does in Western countries.
“Currently, survival rates for breast cancer are low in India and there is not an effective screening program,” Yathish Kumar, a physician with Panacea Hospitals and investigator on the study, said in a statement. “Using blood as the sample material and being able to screen earlier is thus an extremely attractive proposition and would enable us to start tackling the problem effectively.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.